In this issue:
Predictors of discontinuation of hormonal therapy
Accurately predicting response to endocrine therapy
CEP17 and TOP2A predict anthracycline benefit
Does coffee have a role in breast cancer therapy?
Assessing first-line regimens in triple-negative disease
Safe to omit RT in some older women
APBI as effective as WBI in early-stage disease
Aspirin use and survival in breast cancer
Surgery in low-grade DCIS: no survival advantage
Please login below to download this issue (PDF)